Israel - English - Ministry of Health

teva israel ltd - pravastatin sodium - tablets - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels pravastatin is indicated to: - reduce the risk of recurrent myocardial infarction. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attack (tia). *hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - modafinil, quantity: 100 mg - tablet - excipient ingredients: magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; methylcellulose - modafinil is indicated: ? to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy; ? to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate; ? as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - armodafinil, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; microcrystalline cellulose - ?to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy,?to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate,?as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; aluminium magnesium silicate; lactose monohydrate; purified talc; maize starch; croscarmellose sodium; magnesium stearate - modafinil is indicated:,? to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy;,? to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate;,? as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: aluminium magnesium silicate; lactose monohydrate; croscarmellose sodium; povidone; maize starch; magnesium stearate; purified talc - modafinil is indicated:,? to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy;,? to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate;,? as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - modafinil, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; pregelatinised maize starch; croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose - modafinil-teva is indicated: to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy; to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate; as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - modafinil, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; pregelatinised maize starch; croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose - dafinil is indicated: to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy; to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate; as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; microcrystalline cellulose; ethanol; purified water; mannitol; magnesium stearate; crospovidone - - to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy; - to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate; - as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - armodafinil, quantity: 150 mg - tablet, uncoated - excipient ingredients: povidone; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; lactose monohydrate; magnesium stearate - ?to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy,?to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate ,?as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - armodafinil, quantity: 250 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; povidone; pregelatinised maize starch; magnesium stearate - ?to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy,?to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate,?as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.